ProMACE-CytaBOM regimen

WikiDoc Resources for ProMACE-CytaBOM regimen
Articles
Most recent articles on ProMACE-CytaBOM regimen Most cited articles on ProMACE-CytaBOM regimen Review articles on ProMACE-CytaBOM regimen Articles on ProMACE-CytaBOM regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on ProMACE-CytaBOM regimen Images of ProMACE-CytaBOM regimen Photos of ProMACE-CytaBOM regimen Podcasts & MP3s on ProMACE-CytaBOM regimen Videos on ProMACE-CytaBOM regimen
Evidence Based Medicine
Cochrane Collaboration on ProMACE-CytaBOM regimen Bandolier on ProMACE-CytaBOM regimen TRIP on ProMACE-CytaBOM regimen
Clinical Trials
Ongoing Trials on ProMACE-CytaBOM regimen at Clinical Trials.gov Trial results on ProMACE-CytaBOM regimen Clinical Trials on ProMACE-CytaBOM regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on ProMACE-CytaBOM regimen NICE Guidance on ProMACE-CytaBOM regimen NHS PRODIGY Guidance FDA on ProMACE-CytaBOM regimen CDC on ProMACE-CytaBOM regimen
Books
Books on ProMACE-CytaBOM regimen
News
ProMACE-CytaBOM regimen in the news Be alerted to news on ProMACE-CytaBOM regimen News trends on ProMACE-CytaBOM regimen
Commentary
Blogs on ProMACE-CytaBOM regimen
Definitions
Definitions of ProMACE-CytaBOM regimen
Patient Resources / Community
Patient resources on ProMACE-CytaBOM regimen Discussion groups on ProMACE-CytaBOM regimen Patient Handouts on ProMACE-CytaBOM regimen Directions to Hospitals Treating ProMACE-CytaBOM regimen Risk calculators and risk factors for ProMACE-CytaBOM regimen
Healthcare Provider Resources
Symptoms of ProMACE-CytaBOM regimen Causes & Risk Factors for ProMACE-CytaBOM regimen Diagnostic studies for ProMACE-CytaBOM regimen Treatment of ProMACE-CytaBOM regimen
Continuing Medical Education (CME)
CME Programs on ProMACE-CytaBOM regimen
International
ProMACE-CytaBOM regimen en Espanol ProMACE-CytaBOM regimen en Francais
Business
ProMACE-CytaBOM regimen in the Marketplace Patents on ProMACE-CytaBOM regimen
Experimental / Informatics
List of terms related to ProMACE-CytaBOM regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:Prednisone-Methotrexate-Adriamycin-Cytoxan-Etoposide-Cytarabine-Bleomycin-Oncovin-Methotrexate Regimen; ProMACE-CytaBOM Regimen

Overview

ProMACE-CytaBOM regimen refers to a regimen consisting of a non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine (oncovin) and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin's lymphoma

Regimen

ProPrednisone MMethotrexate ADoxorubicin (Adriamycin)

CytaCyclophosphamide

EEtoposide

CytaCytarabine

BBleomycin

OVincristine (Oncovin)

MMethotrexate

Indications

• Non-Hodgkin lymphoma<ref name="pmid15459544">Isogai R, Kawada A, Hashimoto K, Aragane Y, Tezuka T, Maeda Y; et al. (2004). "Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy". Dermatology. 209 (3): 243–5. doi:10.1159/000079901. PMID 15459544.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link) </ref